salicylates and Dermatitis--Atopic

Topics: Administration, Topical; Adolescent; Anti-Inflammatory Agents; Candidiasis; Child, Preschool; Dermatitis; Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Occupational; Dermatitis, Seborrheic; Eczema; Environmental Exposure; Female; Glucocorticoids; Humans; Hyperhidrosis; Infant; Male; Photosensitivity Disorders; Saccharomyces cerevisiae; Salicylates; Steroids; Sulfur

Topics: Alcohols; Cosmetics; Dermatitis, Atopic; Dermatitis, Contact; Drug Hypersensitivity; Eczema; Humans; Lanolin; Salicylates; Skin Tests

UR-1505 is a new small molecule with immune modulator properties intended for the topical treatment of inflammatory skin diseases that has shown anti-inflammatory effects in models of skin inflammation. We compared the activity of UR-1505 ointment against its vehicle in the treatment of atopic dermatitis. Secondary objectives included exploring dose response, safety, and local tolerability of UR-1505.. Patients with AD lesions on 2 symmetrical topographic areas (arms, leg, or trunk) were included in this unicenter randomized, double-blind, within-patient, controlled Phase II exploratory trial and received simultaneously 2 different treatments (0.5%, 1%, or 2% UR-1505 and vehicle or 0.1% tacrolimus ointment) once daily during 28 days. The primary efficacy end point was the change from baseline in the Investigator Global Assessment score at Day 28. Secondary end points were percentage of area clearance, local Eczema Area Severity Index (local EASI), and local tolerability. A linear mixed model was used, fitting treatment, body side, and group (treatment at the contralateral side) as fixed factors and the patient as a random effect.. Twenty-eight patients were randomized and 25 patients were included in the per protocol analysis, with 50 evaluable lesions (n = 13 for vehicle, n = 8 for UR-1505 0.5%, n = 9 for 1% UR-1505, n=8 for 2% UR-1505, and n=12 for tacrolimus). The mean Investigator Global Assessment score change from baseline at Day 28 was -1.7 for vehicle, -1.0, -1.2, and -1.5 for 0.5%, 1%, and 2% UR-1505, respectively, and -2.6% for tacrolimus (P = 0.002). No serious nor causal adverse reactions were reported in this study, but patients reported numerous local symptoms after product applications, especially itching, tingling, tightness, and heat/burning sensations at frequencies that were similar for vehicle, 1% UR-1505, and 2% UR-1505; more frequent with 0.5% UR-1505; and lowest for tacrolimus.. This study found that UR-1505 may not be a suitable option for the treatment of atopic dermatitis due to its lack of clinically relevant effect compared with its vehicle and 0.1% tacrolimus ointment.

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Atopic; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Ointments; Salicylates; Tacrolimus; Treatment Outcome; Young Adult

Topics: Adolescent; Adult; Betamethasone; Child; Dermatitis, Atopic; Dermatologic Agents; Drug Combinations; Humans; Middle Aged; Ointments; Psoriasis; Remission Induction; Salicylates; Solutions; Time Factors

Recommendations for topical dermatologic therapy of the most common skin diseases in infancy and childhood are given with tabular summaries. They are concerned with diaper dermatitis, seborrhoeic dermatitis, atopic dermatitis, scabies and pediculosis. Special attention is given to topical steroid therapy in seborrhoeic and atopic dermatitis and to the possible neurotoxic side-effects of Lindan, the most effective substance against scabies and pediculosis.

Topics: Administration, Topical; Antifungal Agents; Balneology; Child; Child, Preschool; Cortisone; Dermatitis, Atopic; Dermatitis, Seborrheic; Diaper Rash; Hexachlorocyclohexane; Histamine H1 Antagonists; Humans; Infant; Ointments; Salicylates; Scabies; Skin Diseases; Zinc Oxide

Topics: Animals; Cheilitis; Chemical Phenomena; Chemistry; Dermatitis, Atopic; Dermatitis, Contact; Dermatologic Agents; Drug Hypersensitivity; Female; Guinea Pigs; Humans; Patch Tests; Salicylates

Topics: Brain Neoplasms; Cerebrovascular Disorders; Dermatitis, Atopic; Humans; Lupus Erythematosus, Systemic; Orosomucoid; Polarography; Psoriasis; Salicylates

Topics: Bacterial Infections; Cold Temperature; Dermatitis, Atopic; Drug Eruptions; Drug Hypersensitivity; Food Hypersensitivity; Histamine Release; Hot Temperature; Humans; Hypersensitivity, Delayed; Hypersensitivity, Immediate; Insect Bites and Stings; Light; Respiratory Hypersensitivity; Salicylates; Urticaria; Virus Diseases

Sebaceous gland activity in the newborn and children is extensive at first in the epidermis, and later decreases owing to defective operation of the sweat glands, circulation changes, growth of the hair, and a predisposition to infection, for which significant treatment is required. In addition to the genetic "typus neurodermiticus", pharmaceutical, alimentary and respiratory allergens and psychological factors may play a part in the appearance of atopical dermatitis. Onset is usually in the 2nd to 6th month and the side of the face and the scalp are affected. The clinical picture varies considerably with age and includes sanious foci covered with scabs on the head and eczema flexurarum. Differences in family history, age and the location of sites will distinguish this form from seborrhoeic dermatitis. Gluteal dermitis is secondary to congestion caused by dampness, rugging and soaking, and the action of stools and urine (bacterial amniogenesis). The main complications of neonatal and infantile impetigo are: glomerulonephritis, exfoliative dermatitis, pulmonary abscess, pulmonitis and osteomyelitis; phlyctenular, serpiginous impetigo with large and small bullae is particularly important. Treatment of neonatal and infantile dermatosis must take account of the fact that increased reabsorption and congestion are contraindications for the local application of corticoids and preparations containing salicylic and boric acid.

Topics: Anti-Bacterial Agents; Child, Preschool; Dermatitis, Atopic; Dermatitis, Seborrheic; Diagnosis, Differential; Diet Therapy; Eczema; Humans; Hypnotics and Sedatives; Impetigo; Infant; Infant, Newborn; Infant, Newborn, Diseases; Neurodermatitis; Nystatin; Oils; Ointments; Salicylates; Skin Diseases

Topics: Adult; Aged; Chronic Disease; Dermatitis, Atopic; Dermatitis, Contact; Drug Synergism; Eczema; Female; Flumethasone; Fluorine; Glucocorticoids; Humans; Lupus Erythematosus, Discoid; Male; Middle Aged; Ointments; Pregnanes; Psoriasis; Salicylates

Topics: Child; Dermatitis, Atopic; Eczema; Humans; Infant; Salicylates; Sodium Salicylate

Topics: Child; Dermatitis, Atopic; Eczema; Humans; Infant; Salicylates; Sodium Salicylate